Trial Search Results

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: The V Foundation for Cancer Research

Stanford Investigator(s):


  • Drug: arsenic trioxide




Inclusion Criteria:

   - Patients with basal cell carcinoma (BCC)

   - Patients ineligible for curative locoregional treatment and have either progressed on,
   did not tolerate, unwilling to try or ineligible for investigational smoothened
   antagonist such as vismodegib (GDC 0449), XL 139 (BMS 833923), IPI- 926, LDE225 and

   - Life expectancy estimate > 3 months

   - Performance status Eastern Cooperative Oncology Group (ECOG) 0-2

   - Absolute neutrophil count >= 1,500/mcL

   - Platelets >= 100,000/mcL

   - Total bilirubin within normal institutional limits

   - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
   [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
   =< 2.5 x institutional upper limit of normal

   - Creatinine within normal institutional limits

   - Corrected QT interval (QTC) by 12 lead electrocardiogram (EKG) < 450 msecs

   - Serum potassium within normal limits

   - Magnesium within normal limits

   - Calcium within normal limits

   - Include the following: ability to understand and the willingness to sign a written
   informed consent document

   - Patients must have evaluable tumor and be potentially eligible for pre and post ATO
   tumor biopsy

Exclusion Criteria:

   - Concurrent use of other Investigational agents is prohibited

   - Patients with cardiac arrhythmias are excluded

   - Patients receiving potassium wasting diuretics or amphotericin, while not excluded,
   must be noted to have theoretically increased arrhythmia risks with ATO

   - Uncontrolled intercurrent illness including, but not limited to, ongoing or active
   infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, recurrent seizure history or psychiatric illness/social situations that
   would limit compliance with study requirements

   - Pregnant women and breastfeeding women are excluded from this study

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305